Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine how multiple myeloma responds when the
study drug vorinostat is added to the standard treatment of bortezomib and pegylated
liposomal doxorubicin (PLD). After participants complete the three drug combination and if
their multiple myeloma has decreased, the investigators also want to learn what effects (both
good and bad) when vorinostat and bortezomib are given to people with multiple myeloma over a
longer period of time. This type of treatment is called 'Maintenance Therapy'.